Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Could PLS represent a UMN-predominant ALS syndrome?
Corcia P, Couratier P, Ingre C. Corcia P, et al. Among authors: ingre c. Rev Neurol (Paris). 2024 May 22:S0035-3787(24)00529-0. doi: 10.1016/j.neurol.2024.04.006. Online ahead of print. Rev Neurol (Paris). 2024. PMID: 38782644 Review.
Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay.
Kmezic I, Gustafsson R, Fink K, Svenningsson A, Samuelsson K, Ingre C, Olsson T, Hansson M, Kockum I, Adzemovic MZ, Press R. Kmezic I, et al. Among authors: ingre c. Front Immunol. 2023 Nov 23;14:1241199. doi: 10.3389/fimmu.2023.1241199. eCollection 2023. Front Immunol. 2023. PMID: 38077366 Free PMC article.
Neurodegenerative biomarkers outperform neuroinflammatory biomarkers in amyotrophic lateral sclerosis.
Kläppe U, Sennfält S, Lovik A, Finn A, Bofaisal U, Zetterberg H, Blennow K, Piehl F, Kmezic I, Press R, Samuelsson K, Månberg A, Fang F, Ingre C. Kläppe U, et al. Among authors: ingre c. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Feb;25(1-2):150-161. doi: 10.1080/21678421.2023.2263874. Epub 2024 Jan 23. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 37789557
A randomized, double-blind, placebo-controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis.
Weemering DN, Midei M, Milner P, Gopalakrishnan V, Kumar A, Dannenberg AJ, Bunte TM, Foucher J, Ingre C, Ķēniņa V, Rallmann K, van den Berg LH, van Eijk RPA. Weemering DN, et al. Among authors: ingre c. Eur J Neurol. 2023 Dec;30(12):3722-3731. doi: 10.1111/ene.16020. Epub 2023 Aug 21. Eur J Neurol. 2023. PMID: 37550954 Clinical Trial.
Validity and reliability measures of the Swedish Karolinska version of the Edinburgh Cognitive and Behavioral ALS Screen (SK-ECAS).
Foucher J, Winroth I, Lovik A, Sennfält S, Pereira JB, Fang F, Lule D, Andersen PM, Ingre C. Foucher J, et al. Among authors: ingre c. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Jul 31:1-6. doi: 10.1080/21678421.2023.2239857. Online ahead of print. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 37519256
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.
Shefner JM, Al-Chalabi A, Andrews JA, Chio A, De Carvalho M, Cockroft BM, Corcia P, Couratier P, Cudkowicz ME, Genge A, Hardiman O, Heiman-Patterson T, Henderson RD, Ingre C, Jackson CE, Johnston W, Lechtzin N, Ludolph A, Maragakis NJ, Miller TM, Mora Pardina JS, Petri S, Simmons Z, Van Den Berg LH, Zinman L, Kupfer S, Malik FI, Meng L, Simkins TJ, Wei J, Wolff AA, Rudnicki SA. Shefner JM, et al. Among authors: ingre c. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5-6):523-534. doi: 10.1080/21678421.2023.2216223. Epub 2023 May 30. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 37254449 Clinical Trial.
54 results